Leukemic mastopathy

Int J Hematol. 2016 Apr;103(4):357-8. doi: 10.1007/s12185-016-1948-8. Epub 2016 Feb 8.

Authors

Enrico Schalk¹, Florian H Heidel^{2

3}

Affiliations

¹ Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany. enrico.schalk@med.ovgu.de.
² Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
³ Internal Medicine II, Hematology and Oncology, Jena University Hospital and Medical Faculty, Friedrich-Schiller-University Jena, Jena, Germany.

PMID: 26857154
DOI: 10.1007/s12185-016-1948-8

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents, Alkylating / therapeutic use
Antineoplastic Agents, Hormonal / therapeutic use
Breast / drug effects
Breast / pathology*
Cyclophosphamide / therapeutic use
Dexamethasone / therapeutic use
Female
Fibrocystic Breast Disease / complications*
Fibrocystic Breast Disease / drug therapy
Fibrocystic Breast Disease / pathology
Humans
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications*
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
T-Lymphocytes / drug effects
T-Lymphocytes / pathology*

Substances

Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Dexamethasone
Cyclophosphamide